Quest Diagnostics Incorporated (DGX)
| Market Cap | 19.46B |
| Revenue (ttm) | 10.16B |
| Net Income (ttm) | 892.00M |
| Shares Out | 111.64M |
| EPS (ttm) | 7.91 |
| PE Ratio | 22.05 |
| Forward PE | 17.65 |
| Dividend | $3.20 (1.84%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 434,248 |
| Open | 174.21 |
| Previous Close | 173.65 |
| Day's Range | 174.17 - 175.50 |
| 52-Week Range | 135.47 - 179.99 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 185.07 (+6.16%) |
| Earnings Date | Jul 22, 2025 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,... [Read more]
Financial Performance
In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $185.07, which is an increase of 6.16% from the latest price.
News
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss...
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J. , May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend...
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors th...
Quest Diagnostics: A Leader But Waiting For Better Price
Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to ...
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.
Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief...
Quest beats quarterly profit estimates on strong demand for diagnostic tests
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter
Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow.
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024...
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and sp...
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to scree...
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025
SECAUCUS, N.J. , April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial resul...
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day
Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance...
Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI
SUNNYVALE, Calif. and SECAUCUS, N.J.
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J...
Quest Diagnostics to Host Investor Day on March 19, 2025
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financi...
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. ...
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year
SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World'...
Quest Diagnostics Incorporated (DGX) Q4 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conf...
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 20...
Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND , Jan. 27, 2025 /PRNewswire/ -- Quest Diag...
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J. , Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diag...